Market data loadingS&P 500--NASDAQ--Data as of latest ETNo timestamp

Verastem, Inc. (VSTM) Cash Flow Statement

Verastem, Inc. (VSTM) generated -$162.2M of operating cash flow over the twelve months to 2026-06-30, spent $0 on capital expenditure and had free cash flow of -$162.2M, according to EquiReason's reading of its SEC filings.

Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason

VSTMVerastem, Inc.Follow VSTM — free
Biotechnology · Healthcare
—
Price chart with a free account
Market cap
909.3M
P/E TTM
—
Dividend yield
—
52-week
—
Next earnings
2 Nov, in 9 days
LineFY2018
Dec 18
FY2019
Dec 19
FY2020
Dec 20
FY2021
Dec 21
FY2022
Dec 22
FY2024
Dec 24
FY2025
Dec 25
TTM
Jun 26
Trend
Operating cash flow-74.5-138.5-33.5-53.5-63.7-104.8-137.5-162.2
Capital expenditure1.50.00.00.2—0.00.0-0.0
Free cash flow-76.0-138.5-33.5-53.7—-104.8-137.5-162.2
Stock-based compensation6.78.58.17.76.07.39.4—

USD millions · SEC XBRL

Verastem, Inc. — questions

What is Verastem, Inc.'s operating cash flow?
-$162.2M over the twelve months to 2026-06-30.
How much does Verastem, Inc. spend on capital expenditure?
$0 over the twelve months to 2026-06-30.
What is Verastem, Inc.'s free cash flow?
-$162.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.

Every figure on this page comes from Verastem, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.

How these figures are read: methodology · EquiReason.